BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 31239236)

  • 21. Magnetic resonance/ultrasound fusion targeted biopsy of the prostate can be improved by adding systematic biopsy.
    Cauni VM; Stanescu D; Tanase F; Mihai B; Persu C
    Med Ultrason; 2021 Aug; 23(3):277-282. PubMed ID: 34113933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
    Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
    Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
    Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
    J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Multiparametric MRI and MRI-TRUS fusion biopsy in patients with prior negative prostate biopsy].
    Kesch C; Radtke JP; Distler F; Boxler S; Klein T; Hüttenbrink C; Hees K; Roth W; Roethke M; Schlemmer HP; Hohenfellner M; Hadaschik BA
    Urologe A; 2016 Aug; 55(8):1071-7. PubMed ID: 27168038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic prostate biopsy still matters: A comprehensive analysis of MRI/TRUS-fusion targeted prostate biopsies across different indications.
    Westhoff N; Baeßler B; von Hardenberg J; Hetjens S; Porubsky S; Siegel F; Martini T; Michel MS; Attenberger U; Ritter M
    Urol Oncol; 2019 Oct; 37(10):678-687. PubMed ID: 31375340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate.
    Maxeiner A; Kittner B; Blobel C; Wiemer L; Hofbauer SL; Fischer T; Asbach P; Haas M; Penzkofer T; Fuller F; Miller K; Cash H
    BJU Int; 2018 Aug; 122(2):211-218. PubMed ID: 29569320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies.
    Arsov C; Rabenalt R; Blondin D; Quentin M; Hiester A; Godehardt E; Gabbert HE; Becker N; Antoch G; Albers P; Schimmöller L
    Eur Urol; 2015 Oct; 68(4):713-20. PubMed ID: 26116294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.
    Hansen NL; Kesch C; Barrett T; Koo B; Radtke JP; Bonekamp D; Schlemmer HP; Warren AY; Wieczorek K; Hohenfellner M; Kastner C; Hadaschik B
    BJU Int; 2017 Nov; 120(5):631-638. PubMed ID: 27862869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined MRI-TRUS fusion targeted and systematic biopsy versus systematic biopsy alone for the detection of prostate cancer: protocol for a prospective single-centre trial.
    Liu W; Kadier A; Shen D; He Y; Dong S; Zhu K; Xu G; Zhao B; Mao S; Guo C; Yao X; Wei Q; Han D; Yang B
    BMJ Open; 2024 Mar; 14(3):e080593. PubMed ID: 38431292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer.
    Porpiglia F; Manfredi M; Mele F; Cossu M; Bollito E; Veltri A; Cirillo S; Regge D; Faletti R; Passera R; Fiori C; De Luca S
    Eur Urol; 2017 Aug; 72(2):282-288. PubMed ID: 27574821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnetic Resonance Imaging-targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer.
    Alkema NG; Hoogeveen SFJS; Cauberg ECC; Witte LPW; van 't Veer-Ten Kate M; de Boer E; Hoogland MAM; Blanker MH; Boomsma MF; Steffens MG
    Eur Urol Open Sci; 2022 Oct; 44():125-130. PubMed ID: 36185584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial.
    Exterkate L; Wegelin O; Barentsz JO; van der Leest MG; Kummer JA; Vreuls W; de Bruin PC; Witjes JA; van Melick HHE; Somford DM
    BJU Int; 2023 Mar; 131(3):313-320. PubMed ID: 35993590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive Versus Software Fusion for MRI-targeted Biopsy: Experience Before and After Implementation of Fusion.
    Monda SM; Vetter JM; Andriole GL; Fowler KJ; Shetty AS; Weese JR; Kim EH
    Urology; 2018 Sep; 119():115-120. PubMed ID: 29940232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transrectal ultrasound examination of prostate cancer guided by fusion imaging of multiparametric MRI and TRUS: avoiding unnecessary mpMRI-guided targeted biopsy.
    Xu G; Li JH; Xiang LH; Yang B; Chen YC; Sun YK; Zhao BH; Wu J; Sun LP; Xu HX
    Asian J Androl; 2023; 25(3):410-415. PubMed ID: 36348578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China.
    Dai Z; Liu Y; Huangfu Z; Wang L; Liu Z
    Med Sci Monit; 2021 Aug; 27():e930234. PubMed ID: 34365459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
    Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
    Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy: A Prospective Randomized Trial.
    Saner YM; Wiesenfarth M; Weru V; Ladyzhensky B; Tschirdewahn S; Püllen L; Bonekamp D; Reis H; Krafft U; Heß J; Kesch C; Darr C; Forsting M; Wetter A; Umutlu L; Haubold J; Hadaschik B; Radtke JP
    Eur Urol Oncol; 2023 Feb; 6(1):49-55. PubMed ID: 36175281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer.
    Zhang X; Hong H; Liang D
    Cancer Imaging; 2022 Oct; 22(1):60. PubMed ID: 36258247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is targeted magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy enough for the detection of prostate cancer in patients with PI-RADS ≥3: Results of a prospective, randomized clinical trial.
    Zhang J; Zhu A; Sun D; Guo S; Zhang H; Liu S; Fu Q; Zhang K
    J Cancer Res Ther; 2020; 16(7):1698-1702. PubMed ID: 33565519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective randomized controlled trial comparing target prostate biopsy alone approach vs. target plus standard in naïve patients with positive mpMRI.
    Porpiglia F; Checcucci E; DE Cillis S; Piramide F; Amparore D; Piana A; Volpi G; Granato S; Zamengo D; Stura I; Alladio E; Migliaretti G; DE Luca S; Bollito E; Gned D; DI Dio M; Autorino R; Manfredi M; Fiori C
    Minerva Urol Nephrol; 2023 Feb; 75(1):31-41. PubMed ID: 36626117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.